Soneira Completes Dosing of First Cohort in Phase 1 Clinical Study of Pharmaceutical-grade Ibogaine

Health Canada-authorized study will generate foundational safety data to support the clinical development of SON-001

DENVER, Nov. 17, 2026—Soneira Inc., PBC, a clinical-stage biotechnology company developing novel therapies for serious neuropsychiatric and neurological conditions, today announced that it has completed dosing of the first cohort of participants in a Phase 1 clinical study of SON-001, the company’s investigational pharmaceutical-grade ibogaine tablet. The study, authorized by Health Canada, is being conducted in healthy adult volunteers as the initial step in the development of SON-001 for traumatic brain injury (TBI)-associated disabilities. 

The goal of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of SON-001. The resulting data will be used to inform dose selection, safety monitoring and the design of future clinical studies across a range of conditions.

Soneira’s Phase 1 clinical study is informed in part by peer-reviewed research into the potential use of ibogaine to treat brain-related disorders, pioneered by the Stanford Brain Stimulation Lab. The company, founded in 2023 to further ibogaine research led by the late Nolan Williams, M.D., has established the manufacturing, regulatory and clinical foundation to support this as well as future clinical studies

“As co-senior author of the initial Stanford ibogaine study published in Nature Medicine, I joined my colleagues in calling for larger, controlled trials as the necessary next step,” said Ian Kratter, M.D., Ph.D., chief medical officer of Soneira. “I have long believed that people living with TBI and its associated disabilities, who have no approved drug treatment options, deserve a therapy developed according to the highest scientific standards. Soneira’s study is the next step forward in the journey to understand the potential use of SON-001 in the treatment of TBI.”

About Soneira

Soneira Inc., PBC is a clinical-stage biotechnology company developing novel therapies for serious neuropsychiatric and neurological conditions. The company’s lead program, SON-001, is an investigational pharmaceutical-grade ibogaine tablet that has not been approved for use by any regulatory authority. As a public benefit corporation, Soneira considers the effects of its decisions on patients, healthcare providers, employees, communities and the environment as well as the interests of its shareholders.

Through its Healing Forward. Giving Back.™ initiative, Soneira collaborates with like-minded organizations to support mental health awareness, address the stigma surrounding mental health and honor the heritage of Indigenous communities that have nurtured and used ibogaine in traditional ceremonies for centuries. For more information, visit soneirapbc.com.

# # #

Media Contact

Amy Cook
amy@soneirapbc.com
+1 (925) 222-5094